Pimagedine
|  | |||
| Names | |||
|---|---|---|---|
| IUPAC name 2-Aminoguanidine | |||
| Other names 
 | |||
| Identifiers | |||
| 3D model (JSmol) | |||
| ChEMBL | |||
| ChemSpider | |||
| ECHA InfoCard | 100.001.076 | ||
| KEGG | |||
| PubChem CID | |||
| UNII | |||
| CompTox Dashboard (EPA) | |||
| 
 | |||
| 
 | |||
| Properties | |||
| CH6N4 | |||
| Molar mass | 74.085 g/mol | ||
| Density | 1.72 g/ml | ||
| Boiling point | 261 °C (502 °F; 534 K) | ||
| log P | −1.475 | ||
| Related compounds | |||
| Related compounds | Guanidine | ||
| Except where otherwise noted, data are given for materials in their standard state (at 25 °C [77 °F], 100 kPa). Infobox references | |||
Pimagedine, also known as aminoguanidine, is an investigational drug for the treatment of diabetic nephropathy that is no longer under development as a drug. Pimagedine functions as an inhibitor of diamine oxidase and nitric oxide synthase. It acts to reduce levels of advanced glycation end products (AGEs) through interacting with 3-deoxyglucosone, glyoxal, methylglyoxal, and related dicarbonyls. These reactive species are converted to less reactive heterocycles by this condensation reaction.